SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:research.chalmers.se:6ff6cf34-0b06-4749-af36-b370c32f1690"
 

Sökning: onr:"swepub:oai:research.chalmers.se:6ff6cf34-0b06-4749-af36-b370c32f1690" > Avidity-Based Affin...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004021naa a2200469 4500
001oai:research.chalmers.se:6ff6cf34-0b06-4749-af36-b370c32f1690
003SwePub
008200124s2019 | |||||||||||000 ||eng|
024a https://doi.org/10.1021/acssensors.9b013922 DOI
024a https://research.chalmers.se/publication/5150772 URI
040 a (SwePub)cth
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Akkilic, Namiku AstraZeneca AB4 aut
2451 0a Avidity-Based Affinity Enhancement Using Nanoliposome-Amplified SPR Sensing Enables Low Picomolar Detection of Biologically Active Neuregulin 1
264 c 2019-11-14
264 1b American Chemical Society (ACS),c 2019
520 a Biomarkers serve as indicators of disease progression or therapeutic response of an medical intervention, and means for enabling a reliable and sensitive biomarker detection are therefore vital in clinical settings. Most biosensor assays require high-affinity interactions in combination with an enzyme or fluorescent tag to enable detection and frequently employ extensive washing procedures prior to signal readout. Attempts to overcome this limitation by using natural biological partners tend to be demanding, because their very low affinity is frequently not compatible with the need of reaching low limits of detection (LODs), especially for circulating biomarkers that possess short half-lives. To address these challenges, we developed a label-free surface plasmon resonance (SPR) platform for the detection of neuregulin 1 (NRG1) using ErbB4-modified liposomes offering both signal amplification and affinity enhancement via functional multivalent interactions. Through the functional avidity interaction between NRG1 and ErbB4, an LOD of 3.5 picomolar was reached, which is about 60-fold higher than traditional SPR and miniaturized immunoassays. The biosensor displays also an 8-fold higher sensitivity when compared with a single-molecule immunoassay employing the natural binding partner rather than a high-affinity antibody as one of the interaction partners. In fact, the liposome-induced avidity between NRG1 and ErbB4 offered an LOD that was comparable to that obtained using a high-affinity antibody and enabled detection of NRG1 in plasma with a LOD of 36 pM. Employing the liposome-enhanced platform in conjunction with a low-affinity biomarker receptor thus enables the assessment of the functional state of the biomarker at competitive LODs and eliminates the need for high-affinity antibodies.
650 7a NATURVETENSKAPx Kemix Analytisk kemi0 (SwePub)104012 hsv//swe
650 7a NATURAL SCIENCESx Chemical Sciencesx Analytical Chemistry0 (SwePub)104012 hsv//eng
650 7a NATURVETENSKAPx Fysikx Annan fysik0 (SwePub)103992 hsv//swe
650 7a NATURAL SCIENCESx Physical Sciencesx Other Physics Topics0 (SwePub)103992 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Läkemedelskemi0 (SwePub)301032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Medicinal Chemistry0 (SwePub)301032 hsv//eng
653 a neuregulin
653 a biomarker
653 a avidity
653 a biosensing
653 a liposome
653 a receptor
653 a surface plasmon resonance
700a Liljeblad, Mathiasu AstraZeneca AB4 aut
700a Blaho, Stefanu AstraZeneca AB4 aut
700a Hölttä, Mikkou AstraZeneca AB4 aut
700a Höök, Fredrik,d 1966u Chalmers tekniska högskola,Chalmers University of Technology4 aut0 (Swepub:cth)fredrikh
700a Geschwindner, S.u AstraZeneca AB4 aut
710a AstraZeneca ABb Chalmers tekniska högskola4 org
773t ACS Sensorsd : American Chemical Society (ACS)g 4:12, s. 3166-3174q 4:12<3166-3174x 2379-3694
8564 8u https://doi.org/10.1021/acssensors.9b01392
8564 8u https://research.chalmers.se/publication/515077

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy